Efficacy of Gemcitabine and Capecitabine Combined with Stereotactic Body Radiation Therapy in the Treatment of Pancreatic Cancer
Objective To evaluate the clinical efficacy of gemcitabine and capecitabine combined with stereotactic body radiation therapy(SBRT)in the treatment of locally advanced pancreatic cancer.Methods A total of 70 patients with unresectable pancreatic cancer diagnosed in the Fifth Affiliated Hospital of Zhengzhou University from January 2016 to January 2021 were divided into two groups according to treatment options.The observation group was treated with gemcitabine and capecitabine combined with SBRT,the control group was treated with gemcitabine and capecitabine.The clinical efficacy,survival prognosis,adverse reactions and analgesic efficacy of the two groups were analyzed.Results The effective rate of the observation group(82.9％)was higher than that(57.1％)of the control group(P＜0.05).The 1-year progression free survival rate and 1-year overall survival rate of the observation group were 45.7％and 77.1％,which were higher than thecontrol group(22.9％,48.6％)(P＜0.05).The median progression free survival(PFS)and median overall survival(OS)of the observation group were 10.5 and 17.5 months,which were longer than the control group(5.5 and 9.0 months)(P＜0.05).At 4 and 12 weeks after the start of treatment,the numeric rating scale(NRS)pain scores of the observation group were lower than that of the control group(P＜0.05).In addition,there was no statistically difference in the main adverse reactions between the two groups after treatment(P＞0.05).Conclusion Gemcitabine and capecitabine combined with SBRT has a high clinical remission rate for patients with inoperable locally advanced pancreatic cancer,which can improve the clinical efficacy and survival prognosis,can improve the quality of life,and has tolerable adverse reactions,it is a treatment mode worthy of clinical promotion and application.
pancreatic cancerstereotactic body radiation therapygemcitabinecapecitabine
万方数据
维普
